Alnylam Pharmaceuticals ALNY Income Statement (2009-2026)

NASDAQ ALNY
$266.17 +1.67 (+0.63%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Alnylam Pharmaceuticals Quarterly Income Statement

Periods 69 quarters
Latest Jun 2026

Alnylam Pharmaceuticals reported revenue of $1290.95M and net income of $164.49M for the quarter ended Jun 2026, up 66.9% year over year. This income statement covers 69 quarters of results from Jun 2009 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2009 Sep2009 Dec2009 Mar2010 Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue
187.63M258.54M213.26M224.82M264.31M335.04M319.29M318.75M750.53M439.72M494.33M659.83M500.92M593.17M30.00M773.69M1,249.03M1,097.03M1,167.17M1,290.95M
Cost of RevenueCost of Rev
28.09M33.63M23.46M34.04M36.51M46.17M41.43M75.34M79.47M71.97M54.61M67.27M81.98M102.65M70.18M142.03M197.23M267.72M207.52M298.26M
Gross Profit
159.54M224.90M189.80M190.78M227.80M288.86M277.86M243.42M671.06M367.74M439.72M592.55M418.94M490.52M-40.18M631.66M1,051.80M829.31M959.65M992.69M
Operating items
Research & DevelopmentR&D
194.57M229.05M169.89M205.71M245.37M262.04M230.57M248.53M253.18M272.14M261.00M294.14M270.93M300.17M265.12M323.62M358.81M372.22M364.87M413.13M
Selling, General & AdministrativeSG&A
142.07M186.38M154.47M169.98M235.86M210.34M183.66M214.69M199.18M198.12M210.80M248.40M220.99M295.34M239.95M323.31M322.08M325.37M322.55M347.92M
Other Operating ExpensesOther Opex
32.66M37.66M35.63M40.81M41.12M51.27M54.87M85.37M84.31M85.86M65.98M68.67M85.91M102.82M71.04M142.95M200.15M267.72M211.12M298.45M
Operating ExpensesOpex
369.31M453.10M359.99M416.50M522.35M523.65M469.10M548.59M536.66M556.12M537.77M611.21M577.82M698.33M576.11M789.89M881.04M965.32M898.54M1,059.51M
Operating IncomeOp. Inc
-181.68M-194.56M-146.73M-191.69M-258.04M-188.61M-149.81M-229.83M213.87M-116.40M-43.44M48.61M-76.91M-105.16M18.08M-16.20M367.98M131.72M268.64M231.44M
EBIT
-181.68M-194.56M-146.73M-191.69M-258.04M-188.61M-149.81M-229.83M213.87M-116.40M-43.44M48.61M-76.91M-105.16M18.08M-16.20M367.98M131.72M268.64M231.44M
Non-operating items
Non Operating Interest Expenses
40.27M36.82M42.36M42.61M41.08M29.91M28.95M30.04M30.89M31.34M35.25M33.26M34.38M38.97M58.31M61.46M44.40M65.40M69.29M82.05M
Non Operating Investment IncomeNon-Op. Investment Inc.
Interest & Investment IncomeInt & Inv Inc
-0.06M-1.67M-7.22M1.90M7.82M35.81M18.66M21.07M25.43M30.41M29.64M29.18M32.15M31.02M28.67M27.49M28.68M26.63M26.60M28.14M
Other Non Operating IncomeOther Non Op Inc.
17.71M-30.50M-51.27M-42.28M-76.60M-2.57M-12.26M-35.42M-57.66M-20.35M-14.54M-55.70M-29.53M-80.85M9.19M8.86M-74.15M-3.36M-4.29M0.27M
Non Operating IncomeNon Op. Inc.
-22.56M-65.74M-92.62M-82.99M-147.90M-18.41M-22.55M-44.38M-63.13M-21.28M-20.15M-59.78M-31.76M-88.80M-20.45M-25.11M-129.01M-45.46M-46.98M-53.63M
Net income details
EBT
-204.24M-260.30M-239.36M-274.67M-405.94M-207.02M-172.36M-274.21M150.74M-137.69M-63.59M-11.17M-108.66M-193.96M-2.37M-41.31M280.57M86.26M221.65M177.81M
Tax ProvisionsTaxes
0.28M-1.84M0.98M2.73M-0.02M0.47M1.74M1.81M2.99M0.18M2.35M5.72M2.91M-110.19M15.88M30.92M-12.12M-25.28M15.66M13.31M
Profit After TaxPAT
-204.51M-258.46M-240.34M-277.40M-407.48M-208.36M-174.10M-276.02M152.49M-137.87M-65.94M-16.89M-111.57M-93.45M-18.25M-72.23M259.26M113.22M205.99M164.49M
Equity Income
Income from Continuing OperationsIncome (Continuing)
-204.51M-258.46M-240.34M-277.40M-405.92M-207.49M-174.10M-276.02M147.75M-137.87M-65.94M-16.89M-111.57M-83.76M-18.25M-72.23M292.68M111.54M205.99M164.49M
Consolidated Net IncomeConsol Net Inc.
-204.51M-258.46M-240.34M-277.40M-405.92M-207.49M-174.10M-276.02M147.75M-137.87M-65.94M-16.89M-111.57M-83.76M-18.25M-72.23M292.68M111.54M205.99M164.49M
Income towards Parent CompanyParent Net Inc
-204.51M-258.46M-240.34M-277.40M-405.92M-207.49M-174.10M-276.02M147.75M-137.87M-65.94M-16.89M-111.57M-83.76M-18.25M-72.23M292.68M111.54M205.99M164.49M
Net Income towards Common StockholdersNet Income
-204.51M-258.46M-240.34M-277.40M-405.92M-207.49M-174.10M-276.02M147.75M-137.87M-65.94M-16.89M-111.57M-83.76M-18.25M-72.23M292.68M111.54M205.99M164.49M
Additional items
EPS (Basic)
-1.72-2.18-2.00-2.29-3.32-1.71-1.40-2.211.18-1.10-0.52-0.13-0.87-0.66-0.14-0.552.230.851.551.23
EPS (Diluted)
-1.72-2.18-2.00-2.29-3.32-1.71-1.40-2.211.12-1.10-0.52-0.13-0.87-0.66-0.14-0.552.130.831.491.19
Shares Outstanding
119.14M118.45M120.39M120.90M122.17M121.69M124.11M124.66M125.22M124.91M126.14M126.73M128.59M127.65M129.68M130.63M131.45M131.00M132.89M133.61M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
119.14M118.45M120.39M120.90M122.17M121.69M124.11M124.66M131.34M124.91M126.14M126.73M128.59M127.65M129.68M130.63M137.35M134.68M138.23M138.28M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
119.48M120.18M120.73M120.99M122.99M123.92M124.24M124.90M125.45M125.79M126.46M128.02M128.84M129.29M130.31M130.98M131.79M132.38M133.44M133.73M
EBITDA
-181.68M-194.56M-146.73M-191.69M-258.04M-188.61M-149.81M-229.83M213.87M-116.40M-43.44M48.61M-76.91M-105.16M18.08M-16.20M367.98M131.72M268.64M231.44M
Interest ExpensesInt Expense
40.27M36.82M42.36M42.61M41.08M29.91M28.95M30.04M30.89M31.34M35.25M33.26M34.38M38.97M58.31M61.46M44.40M65.40M69.29M82.05M
Tax Rate
-0.14%0.71%-0.41%-0.99%0.01%-0.23%-1.01%-0.66%1.98%-0.13%-3.69%-51.24%-2.68%56.81%-670.73%-74.85%-4.32%-29.31%7.07%7.49%